Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Min Jeong | - |
dc.contributor.author | Hwang, In Gyu | - |
dc.contributor.author | Jang, Joung-Soon | - |
dc.contributor.author | Choi, Jin Hwa | - |
dc.contributor.author | Park, Byeong-Bae | - |
dc.contributor.author | Chang, Myung Hee | - |
dc.contributor.author | Kim, Seung Tae | - |
dc.contributor.author | Park, Se Hoon | - |
dc.contributor.author | Kang, Myoung Hee | - |
dc.contributor.author | Kang, Jung Hun | - |
dc.date.accessioned | 2021-09-06T12:29:14Z | - |
dc.date.available | 2021-09-06T12:29:14Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2012-12 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/106775 | - |
dc.description.abstract | Purpose Little is known about outcomes in the use of third-line chemotherapy in cases of advanced gastric cancer (AGC). The primary aim of this retrospective study was to evaluate outcomes of docetaxel-based chemotherapy in patients with AGC that progressed after both oxaliplatin-based and irinotecan-based regimens. Materials and Methods Eligible patients were those with AGC who had previous chemotherapy including fluoropyrimidine and oxaliplatin as well as fluoropyrimidine and irinotecan and who received subsequent docetaxel-based chemotherapy. Thirty-five patients were retrospectively recruited from 5 medical centers in Korea. Patients received either weekly or 3 weekly with docetaxel +/- cisplatin. Results Thirty-one out of 35 patients were evaluated for treatment response. A total of 94 cycles of chemotherapy (median, 2; range, 1 to 7) were administered. The overall response rate was 14.3%, and the disease control rate was 45.7%. The median progression-free survival (PFS) was 1.9 months (95% confidence interval [Cl], 1.1 to 2.7 months). The median overall survival (OS) was 3.6 months (95% Cl, 2.8 to 4.4 months). PFS and OS were significantly prolonged in patients of the Eastern Cooperative Oncology Group, with performance status of 0 or 1 in multivariate analysis (PFS: hazard ratio[HR], 0.411; 95% Cl, 0.195 to 0.868; p=0.020 and OS: HR, 0.390; 95% Cl, 0.184 to 0.826; p=0.014, respectively). Four of the 35 patients enrolled in the study died due to infection associated with neutropenia. Conclusion Our findings suggest that salvage docetaxel-based chemotherapy is a feasible treatment option for AGC patients with good performance status (PS), whereas chemotherapy for patients with poor PS (PS <= 2) should be undertaken with caution for those who previously failed oxaliplatin- and irinotecan-based regimens. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN CANCER ASSOCIATION | - |
dc.subject | SUPPORTIVE CARE | - |
dc.subject | COMBINATION CHEMOTHERAPY | - |
dc.subject | 2ND-LINE CHEMOTHERAPY | - |
dc.subject | SALVAGE CHEMOTHERAPY | - |
dc.subject | PLUS | - |
dc.subject | FLUOROURACIL | - |
dc.subject | LEUCOVORIN | - |
dc.subject | SURVIVAL | - |
dc.subject | FOLFIRI | - |
dc.title | Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Seung Tae | - |
dc.identifier.doi | 10.4143/crt.2012.44.4.235 | - |
dc.identifier.scopusid | 2-s2.0-84873972371 | - |
dc.identifier.wosid | 000313303100003 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, v.44, no.4, pp.235 - 241 | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.citation.title | CANCER RESEARCH AND TREATMENT | - |
dc.citation.volume | 44 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 235 | - |
dc.citation.endPage | 241 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001724440 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | SUPPORTIVE CARE | - |
dc.subject.keywordPlus | COMBINATION CHEMOTHERAPY | - |
dc.subject.keywordPlus | 2ND-LINE CHEMOTHERAPY | - |
dc.subject.keywordPlus | SALVAGE CHEMOTHERAPY | - |
dc.subject.keywordPlus | PLUS | - |
dc.subject.keywordPlus | FLUOROURACIL | - |
dc.subject.keywordPlus | LEUCOVORIN | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | FOLFIRI | - |
dc.subject.keywordAuthor | Stomach neoplasms | - |
dc.subject.keywordAuthor | Docetaxel | - |
dc.subject.keywordAuthor | Oxaliplatin | - |
dc.subject.keywordAuthor | Irinotecan | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.